Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).
Allen S. Lichter, MD, ASCO’s former Chief Executive Officer, talks with Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, the 2018 recipient of the Visionary Leader Award, named for Dr. Lichter.
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses phase II study findings on the addition of durvalumab to a taxane-anthracycline–containing chemotherapy in triple-negative breast cancer (Abstract 104).
Rita Elias Assi, MD, of The University of Texas MD Anderson Cancer Center, discusses the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (Abstract 103).
